United Therapeutics Corporation (UTHR)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$536.40−0.98%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $23.0B
- P/E (trailing)
- 19.2
- Forward P/E
- 17.6
- 52-week range
- $409.07 – $609.35
- 52-week change
- +18.58%
- EPS (trailing)
- $27.92
- Analyst rating
- 1.9 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $3.2B (+10.61%)
- Net income
- $1.3B
- Operating margin
- 46.9%
- Diluted EPS
- $27.86
- Free cash flow
- $1.0B
From the company’s annual report on SEC EDGAR.
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
Headquarters: Silver Spring, United States · 1,400 employees · unither.com